Company Description
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States.
Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain.
Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S for the discovery and development of new genetic medicines to treat cardiometabolic diseases.
Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Oct 3, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 102 |
| CEO | Ram Aiyar |
Contact Details
Address: One Kendall Square, Building 600-700 Cambridge, Massachusetts 02139 United States | |
| Phone | 617 468 1999 |
| Website | korrobio.com |
Stock Details
| Ticker Symbol | KRRO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001703647 |
| CUSIP Number | 500946108 |
| ISIN Number | US5009461089 |
| Employer ID | 47-2324450 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ram Aiyar MBA, Ph.D. | Chief Executive Officer, President and Director |
| Nessan Bermingham Ph.D. | Co-Founder and Independent Chairman of the Board |
| Dr. Jean-Francois Formela M.D., MBA | Co-Founder and Independent Director |
| Vineet Agarwal M.B.A. | Chief Financial Officer |
| Andrew Fraley Ph.D. | Co-Founder and Advisor |
| Dr. Joshua Rosenthal Ph.D. | Co-Founder and Advisor |
| Todd Chappell M.B.A. | Chief Operating Officer |
| Jeffrey M. Cerio J.D., Pharm.D. | Senior Vice President and General Counsel |
| Stephanie Engels | Senior Vice President and Head of People and Culture |
| Marco A. Passini Ph.D. | Vice President and Head of CNS biology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 10, 2024 | 424B3 | Prospectus |
| Dec 10, 2024 | 424B3 | Prospectus |
| Dec 9, 2024 | EFFECT | Notice of Effectiveness |
| Dec 9, 2024 | EFFECT | Notice of Effectiveness |
| Dec 6, 2024 | EFFECT | Notice of Effectiveness |
| Dec 6, 2024 | 424B5 | Filing |
| Dec 2, 2024 | POS AM | Post-Effective amendments for registration statement |
| Dec 2, 2024 | POS AM | Post-Effective amendments for registration statement |
| Dec 2, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 21, 2024 | 424B3 | Prospectus |